Giuseppe Fornarini
A5081355165- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Radiopharmaceutical Chemistry and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Renal and related cancers
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Testicular diseases and treatments
- Medical Imaging Techniques and Applications
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
Ospedale Policlinico San Martino
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024
University of Genoa
2014-2024
University of Turin
2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2024
University of Florence
2024
Casa Sollievo della Sofferenza
2024
Carlo Forlanini Hospital
2024
Ospedale Martini
2022
Alleanza Contro il Cancro
2000-2018
No treatment has surpassed platinum-based chemotherapy in improving overall survival patients with previously untreated locally advanced or metastatic urothelial carcinoma. Download a PDF of the Research Summary. We conducted phase 3, global, open-label, randomized trial to compare efficacy and safety enfortumab vedotin pembrolizumab Patients were randomly assigned 1:1 ratio receive 3-week cycles (at dose 1.25 mg per kilogram body weight intravenously on days 1 8) 200 day 1) (enfortumab...
Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, potentially modifiable. We evaluated the potential association of inflammatory BMI with clinical outcome patients renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy.A prospective cohort metastatic RCC treated nivolumab enrolled in Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures inflammation were identified for...
Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% 50% of patients, is a major limitation the treatment chemotherapy-related anemia. We have prospectively evaluated whether intravenous iron can increase proportion patients with anemia who respond darbepoetin.Between December 2004 and February 2006, 149 lung, gynecologic, breast, colorectal cancers >or= 12 weeks planned chemotherapy were enrolled from 33 institutions. Patients required hemoglobin <or= 11 g/L no absolute...
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, identification of prognostic biomarkers is still an unmet clinical need. Methods: This multicenter retrospective study investigated role peripheral-blood inflammatory indices and factors to develop novel score in mRCC receiving at least second-line nivolumab. The complete blood count before first cycle therapy was assessed by...
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably defining lesions and guiding MDT within trials. <b>Methods:</b> We retrospectively identified PCa patients who had 5 or fewer nodal, bone, visceral metastases detected by choline prostate-specific membrane antigen (PSMA) PET/CT underwent stereotactic...
Abstract Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations standard therapy in all mRCC patients regardless International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a option selected patients. However, comparisons between strategies lacking and few real-world data this setting. For reason, regimen choice represents an important issue...
Objective To report the safety and efficacy results of patients enrolled in Italian Nivolumab Renal Cell Cancer Expanded Access Programme. Patients Methods with metastatic renal cell cancer ( mRCC ) previously treated agents targeting vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks. included analysis had received ≥1 dose monitored for adverse events AE s) using Common Terminology Criteria Adverse Events CTCAE v.4.0. Results A total 389...
Reliable and affordable prognostic predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification drive therapeutic options. The SAUL trial investigated the safety efficacy of atezolizumab in a real-world setting on 1004 patients locally advanced or metastatic who progressed to one three prior systemic therapies.Using Italian cohort 267 patients, we role neutrophil-to-lymphocyte ratio (NLR) immune-inflammation index (SII) best performing...
In the last years, theranostics has expanded therapeutic options available for prostate cancer patients. this review, we explore dynamic field and its potential to revolutionize precision medicine cancer. We delve into foundational principles, clinical applications, emerging opportunities, emphasizing synergy between radioligand therapy other systemic treatments. Additionally, address ongoing challenges, including optimizing patient selection, assessing treatment responses, determining role...
Abstract Background Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Patients and Methods Medical records with documented metastatic UC treated by as second-line therapy were retrospectively collected from 88 institutions 23 countries. assessed for overall survival (OS),...
Unspecific bone uptake (UBU) related to [
<h3>Background</h3> Most familial pancreatic cancer (FPC) remains unexplained. The identification of individuals with a high genetic risk developing adenocarcinoma (PC) is important to elucidate its biological basis and critical better define emerging strategies for the detection early neoplasms. <h3>Patients methods</h3> A series 225 consecutively enrolled patients PC were tested <i>CDKN2A</i> mutations. After personal family histories all had been reviewed, subset classified as FPC also...
Abstract Purpose To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([ 223 Ra]RaCl 2 ). Patients methods Baseline neutrophil-to-lymphocyte ratio (NLR), derived NLR (donor), lymphocyte-to-monocyte (LMR), platelet-to-lymphocyte (PLR), systemic inflammation index (SII), Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason (GS) group, number of...